Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways

Yaribeygi, H. and Butler, A. E. and Atkin, S. L. and Katsiki, N. and Sahebkar, A. (2018) Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. Journal of Cellular Physiology, 234 (1). pp. 223-230.

[img] Text
Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease Possible molecular pathways .pdf

Download (730kB)

Abstract

Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti-inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon. © 2018 Wiley Periodicals, Inc.

Item Type: Article
Additional Information: Cited By :19 Export Date: 16 February 2020 CODEN: JCLLA Correspondence Address: Sahebkar, A.; Neurogenic Inflammation Research Center, Mashhad University of Medical SciencesIran; email: sahebkara@mums.ac.ir
Uncontrolled Keywords: canagliflozin chronic kidney disease dapagliflozin empagliflozin inflammation renal failure sodium–glucose cotransporter 2 inhibitors cytokine sodium glucose cotransporter sodium glucose cotransporter 2 inhibitor 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol antidiabetic agent benzhydryl derivative glucose glucoside SLC5A2 protein, human sodium glucose cotransporter 2 uric acid antiinflammatory activity chronic kidney failure hemodynamics immune system nephritis obesity oxidation reduction state priority journal renin angiotensin aldosterone system Review blood blood pressure disease exacerbation drug effect genetics glomerulus filtration rate human metabolism pathology Benzhydryl Compounds Disease Progression Glomerular Filtration Rate Glucosides Humans Hypoglycemic Agents Renal Insufficiency, Chronic Sodium-Glucose Transporter 2 Sodium-Glucose Transporter 2 Inhibitors
Subjects: WJ Urogenital System
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 27 Apr 2020 07:57
Last Modified: 27 Apr 2020 07:57
URI: http://eprints.mums.ac.ir/id/eprint/17575

Actions (login required)

View Item View Item